Loading company…
Zhuhai liquid biopsy company whose LiquidBiopsy system isolates circulating tumor cells from blood for cancer detection.
Founded in 2016 in Zhuhai, China, Sanmed Biotech develops liquid biopsy technologies for early cancer detection and management, particularly lung cancer. Its LiquidBiopsy system is an automated platform that isolates circulating tumor cells and circulating tumor DNA from blood samples. The company has raised RMB 300 million, most recently in a Series B round in April 2021 led by China Merchants Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in